Updates on cytochrome P450-mediated cardiovascular drug interactions

American Journal of Therapeutics

Volumn 16, Issue 2, 2009, Pages 155-163

  Cheng, Judy W M ^a,b   Frishman, William H ^c   Aronow, Wilbert S ^c,d  

^a LONG ISLAND UNIVERSITY   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c WESTCHESTER MEDICAL CENTER   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Cardiovascular drugs; Cytochrome p 450; Drug interactions

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CIMETIDINE; CLOPIDOGREL; CYTOCHROME P450; EFAVIRENZ; ERYTHROMYCIN; FELODIPINE; FLUCONAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IFOSFAMIDE; ITRACONAZOLE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LOSARTAN; METHADONE; MEXILETINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; ONDANSETRON; PROTON PUMP INHIBITOR; RIFAMPICIN; SIMVASTATIN; UNINDEXED DRUG; VERAPAMIL; ZILEUTON; ZOLMITRIPTAN;

ANKLE EDEMA; AREA UNDER THE CURVE; DRUG ACTIVITY; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG WITHDRAWAL; ENZYME ACTIVITY; FLUSHING; HUMAN; LEG EDEMA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 64549130038     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31813e63be     Document Type: Review

References (84)

1. Gonzalez FJ. Molecular genetics of the P-450 superfamily. Pharmac Ther. 1990;45:1-38.
2. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother. 1995;29: 619-624.
3. Guengerich FP, Dannan GA, Wright ST, et al. Purification and characterization of liver microsomal cytochrome P450: electrophoretic, spectral, catalytic and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or B-naphthoflavone. Biochemistry. 1982;21:6019-6030.
4. Waxman DJ, Walsh C. Phenobarbital-induced rat liver cytochrome P-450-purification and characterization of two closely related isozymic forms. J Biol Chem. 1982;2257: 10446-10457.
5. P450 tables. Available at: http://medicine.iupui.edu/flockhart/table.htm Accessed March 25, 2007.
6. Heimark LD, Wienkers L, Dunze K, et al. The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther. 1992;51:398-407.
7. Williamson KM, Patterson JH, McQueen RH, et al. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 1998;63: 316-323.
8. Kazierad DJ, Martin DE, Blum RA, et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther. 1997;62:417-425.
9. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother. 1995;29:619-624.
10. Shinn AF. Clinical relevance of cimetidine drug interctions. Drug Saf. 1992;7;245-67.
11. Levy RH. Cytochrome P450 isoenzyme and antiepileptic drug interactions. Epilepsia. 1995;36(Suppl 5):S8-S13.
12. Venkatesan K. Pharmacokinetic drug interactions with rifampin. Clin Pharmacokinet. 1992;22:47-65.
13. Spinier S, Cheng JWM, Kindwall KE, et al. Possible inhibition of hepatic metabolism of quinidine by erythromycin. Clin Pharmacol Ther. 1995;57:89-94.
14. Nolan PE Jr, Marcus FL, Karol MD, et al. Effect of phenytoin on the clinical pharmacokinetics of amiodarone. J Clin Pharmacol. 1990;30:1112-1119.
15. Gore JM, Haffajee CI, Alpert JS. Interaction of amiodarone and diphenylhydantoin. Am J Cardiol. 1984;54:1145.
16. Marcus FI. Drug interactions with amiodarone. Am Heart J. 1983;106:924-930.
17. Saal AK, Werner JA, Greene HL, et al. Effect of amiodarone on serum quinidine and procainamide levels. Am J Cardiol. 1984;53:1264-1267.
18. DeVane CL, Gill HS, Markowitz JS, et al. Awareness of potential drug interactions may aid avoidance. Ther Drug Monit. 1997;19:366-367.
19. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Throm. Haemost. 2000;84:891-896.
20. Hasegawa M, Sugidachi A, Ogawa T, et al. Stereoselective inhibition of human platelet aggregation by R-l38727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost. 2005;94: 593-598.
21. Kazui M, Ishizuka T, Yamamura N, et al. Mechanism of production of pharmacologically active metabolites of CS-747, a new pro-drug ADP-receptor antagonist. Thromb Haemost. 2001;12(Suppl):P1916.
22. Lau C, L. Waskell LA, Carville D, et al. The antiplatelet activity of clopidogrel is inhibited by atorvastatin but not by pravastatin. Circulation. 2000;102:2086.
23. Lau C, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003;107:32-37.
24. Suri A, Forbes WP, Bramer SL. Effects of CYP3A inhibition on the metabolism of cilostazil. Clin Pharma-cokinet. 1999;37(Suppl 2):61-68.
25. Wood AJ. Drug interactions in hypertension. Hypertension. 1988;ll:II-l-II-3.
26. Herman RJ, Nakamura K, Wilkinson GR, et al. Induction of propranolol metabolism by rifampicin. Br J Clin Pharmacol. 1983;16:565-569.
27. Ishii Y, Nakamura K, Tsutsumi K, et al. Drug interaction between cimetidine and timolol ophthalmic solution: effect on heart rate and intraocular pressure in healthy Japanese volunteers. J Clin Pharmacol. 2000;40: 193-199.
28. Edeki TI, He H, Wood AJ. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction. JAMA. 1995;274:1611-1613.
29. Fuhr U, Dummert AL. The fate of naringin in humans: a key to grapefruit juice-drug interactions. Clin Pharmacol Ther. 1995;58:364-373.
30. Abramowicz M, ed. Grapefruit juice interactions with drugs. Med Lett. 1995;37:63-64.
31. Nordine LH. Erythromycin-felodipine interaction [Letter]. Drug Intell Clin Pharm. 1991;25:1007-1008.
32. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther. 1997;61:410-415.
33. Smith SR, Kendall MJ, Lobo J, et al. Ranitidine and cimetidine drug interactions with single dose and steady-state nifedipine administration. Br J Clin Pharmacol. 1987; 23:311-315.
34. Schwartz JB, Upton RA, Lin ET, et al. Effect of cimetidine or ranitidine administration on nifedipine pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1988;43: 673-680.
35. Fromm MF, Busse D, Kroemer HK, et al. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology. 1996;24:796-801.
36. Chiu SH. The use of in vitro metabolism studies in the understanding of new drugs. J Pharmacol Toxicol Methods. 1993;29:77-83.
37. Jones DR, Gorski JC, Hamman MA, et al. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther. 1999;290:1116-1125.
38. Jones TE, Morris RG, Mathew TH. Diltiazem-cyclosporin pharmacokinetic interaction: dose-response relationship. Br J Clin Pharmacol. 1997;44:499-504.
39. Campana C, Regazzi MB, Buggia I, et al. Clinically significant drug interactions with cyclosporin: an update. Clin Pharmacokinet. 1996;30:141-179.
40. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther. 1998;64:177-182.
41. Zocor prescribing information. Available at: http://www.zocor.com/zocor/ shared/documents/english/pi.pdf. Accessed April 24, 2007.
42. Gruer PJ, Vega JM, Mercuri MF, et al. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol. 1999;84:811-815.
43. Varhe A, Olkkola KT, Neuvonen PJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther. 1996;59:369-375.
44. Ahonen J, Olkkola KT, Salmenpera M, et al. Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Anesthesiology. 1996;85:1246-1252.
45. Varis T, Backman JT, Kivisto KT, et al. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methyl-prednisolone. Clin Pharmacol Ther. 2000;67:215-221.
46. Cook CS, Berry LM. Burton E. Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data. Xenobiotica. 2004;34:215-228.
47. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. 1. Efficacy in modifying plasma lipoproteins and adverse event profile in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151:43-49.
48. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther. 1994;16:366-385.
49. Ayanian JZ, Ruchs CS, Stone RM. Lovastatin and rhabdomyolysis [Letter]. Ann Intern Med. 1988;109: 682-683.
50. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitor. Am J Health Syst Pharm. 1995;52:1639-1645.
51. Kunze KL, Wienkers LC, Thummel KE, et al. Warfarin-fluconazole. 1. Inhibition of human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos. 1996;24:422-128.
52. Black DJ, Kunze KL, Wienkers LC, et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vitro studies. Drug Metab Dispos. 1996;24:422-428.
53. Gillum JG, Isreal DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet.1993;25:450-182.
54. Oberg KC. Delayed elevation of international normalized ratio with concurrent clarithromycin and warfarin therapy. Pharmacotherapy. 1998;18:386-391.
55. Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterolog.y 1985;89:1235-1241.
56. Nemeroff CB, DeVane L, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153:311-320.
57. Brosen K. Are pharmacokinetic drug interactions with SSRIs an issue? Int Clin Psychopharmaco.l 1996;ll(Suppl 1):23-27.
58. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenidine use. JAMA. 1990;264:2788-2790.
59. Hiemke C, Avi P, Jabarin M, et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol. 2002;22:502-506.
60. Honig PK, Woosley RL, Zamani K, et al. Terfenadine-ketoconazole interaction pharmacokinetic and electrocardiographic consequences. JAMA. 1993;269:1513-1518.
61. Kivisto KT, Neuvonen PJ, Klotz U. Inhibition of terfenidine metabolism: pharmacokinetic and pharmacodynamic consequences. Clin Pharmacokinet. 1994;7:1-5.
62. Gillum JG, Isreal DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet. 1993;25:450-482.
63. Oberg K, Bauman JL. QT interval prolongation and Torsades de pointes due to erythromycin lactobionate. Pharmacotherapy. 1995;15:687-692.
64. Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenidine with concomitant administration of erythromycin. Clin Pharmacol Ther. 1992;52:213-218.
65. Amsden GW. Macrolides versus azalides: a drug interaction update. Ann Pharmacother. 1995;29:906-917.
66. Inman W, Kubota K. Tachycardia during cisapride treatment. BMJ. 1992;305:748-749.
67. Arizona Center for Education and Research on Therapeutics. Drugs with risk of Torsades de Pointes. Available at: http:/ /www.arizonacert.org/medical- pros/drug-lists/drug-lists.htm. Accessed March 25, 2007.
68. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl JMed. 2004;351:1089-1096.
69. Dorsey ST, Biblo LA. Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. Am J Emerg Med. 2000;18:227-229.
70. Hoover CA, Carmichael JK, Nolan PE Jr, et al. Cardiac arrest associated with combination cisapride and itraconazole therapy. J Cardiovasc Pharmacol Ther. 1996;1:255-258.
71. Khazan M, Mathis AS. Probable case of torsades de pointes induced by fluconazole. Pharmacotherapy. 2002;22: 1632-1637.
72. Pohjola-Sintonen S, Viitasalo M, Toivonen L, et al. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol. 1993;45:191-193.
73. Zimmermann M, Duruz H, Guinand O, et al. Torsades de pointes after treatment with terfenadine and ketocona-zole. Eur Heart J. 1992;13:1002-1003.
74. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006;50:1570-1572.
75. Bran S, Murray W, Hirsch IB, et al. Long QT syndrome during high dose cisapride. Arch Intern Med. 1995;155:765-768.
76. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med. 1996;335:290-291.
77. Zechnich AD, Hedges JR, Eiselt-Proteau D, et al. Possible interactions with terfenidine or astemizole. West J Med. 1994;160:321-325.
78. Janssen Pharmaceutica stops marking Cisapride in the US. Available at: http://www.fda.gov/bbs/topics/ANSWERS/ANS01007.html. Accessed March 29, 2007.
79. Flockhart DA. Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic? J Clin Psychopharmacol. 1996;16:101-103.
80. Merkel U, Sigusch H, Hoffman A. Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers. Eur J Clin Pharmacol. 1994;46:175-177.
81. Pearson EC, Woosley RL. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf. 2005;14:747-753.
82. Krantz MJ, Lewkowiez L, Hays H, et al. Torsade de pointes associated with very high dose methadone. Ann Intern Med. 2002;137:501-504.
83. Justo D, Gal-Oz A, Paran Y, et al. Methadone associated Torsades de Pointes (polymorphic ventricular tachycardia) in opioid-dependent patients. Addiction. 2006;101:1333-1338.
84. Opie LH. Cardiovascular drug interactions. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular Pharmacotherapeutics, ed 2. New York: McGraw Hill, 2003: 875-891.